Viking Therapeutics Reports Completion Of Enrollment In Phase 2 VENTURE Trial Of Dual GLP-1/GIP Receptor Agonist VK2735 In Patients With Obesity
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics has completed enrollment in its Phase 2 VENTURE trial of VK2735, a dual GLP-1/GIP receptor agonist, in patients with obesity. This marks a significant milestone in the company's clinical development program.
October 23, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics' completion of enrollment for its Phase 2 VENTURE trial of VK2735 could potentially accelerate the company's clinical development program.
The completion of enrollment for the Phase 2 VENTURE trial of VK2735 is a significant milestone for Viking Therapeutics. This could potentially accelerate the company's clinical development program, which may positively impact the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100